ライフサイエンスコーパス: epidermal growth factor receptor

1 ere enriched in Dsg2 C-terminal fragment and epidermal growth factor receptor.

2 itated the c-Src-mediated transactivation of epidermal growth factor receptor.

3 64)Cu-/(177)Lu-cetuximab), that acts as anti-epidermal growth factor receptor.

4 mmatory cytokine TNFalpha and ligands of the epidermal growth factor receptor.

5 in multivesicular body sorting of activated epidermal growth factor receptor.

6 serum albumin and several epitopes on human epidermal growth factor receptor.

7 eptor tyrosine kinases, platelet-derived and epidermal growth factor receptors.

8 ssion of the receptor tyrosine kinases (RTK) epidermal growth factor receptor 1 (EGFR) and human epid

9 3.80; 95% CI, 2.46-5.87; P < .001) and human epidermal growth factor receptor 2 (ERBB2 [formerly HER2

10 first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressin

11 astuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive earl

12 TCO was conjugated to the anti-human epidermal growth factor receptor 2 (HER2) Affibody molec

13 The data suggest that, like human epidermal growth factor receptor 2 (HER2) amplification

14 by key breast cancer oncogenes such as human epidermal growth factor receptor 2 (HER2) and discover i

15 pidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) and HER2/HER3

16 her members of the ErbB family, namely human epidermal growth factor receptor 2 (HER2) and human epid

17 By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by c

18 An example is human epidermal growth factor receptor 2 (HER2) overexpressing

19 e receptor expression and negative for human epidermal growth factor receptor 2 (HER2) overexpression

20 HC) profile, tumors were classified as human epidermal growth factor receptor 2 (HER2) positive (n =

21 sed, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in wome

22 Human epidermal growth factor receptor 2 (HER2) status is one

23 inding, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, and tu

24 ght biomarker subtypes on the basis of human epidermal growth factor receptor 2 (HER2) status, hormon

25 the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status.

26 Dual human epidermal growth factor receptor 2 (HER2) targeting can

27 rican Pathologists recommendations for human epidermal growth factor receptor 2 (HER2) testing in bre

28 rly breast cancer testing positive for human epidermal growth factor receptor 2 (HER2) who were being

29 dy against the extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-

30 or for the detection and estimation of human epidermal growth factor receptor 2 (HER2), a biomarker f

31 The sensitive quantification of Human Epidermal growth factor Receptor 2 (HER2), as a key prog

32 on the basis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone recep

33 vely decreased its activity toward the human epidermal growth factor receptor 2 (HER2)- pY(1196) site

34 majority had hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (72 [

35 anced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breas

36 with oestrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breas

37 A-like tumors, 70.5% of luminal B-like human epidermal growth factor receptor 2 (HER2)-negative tumor

38 patient has hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node

39 ts with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1%

40 and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breas

41 ncluding adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breas

42 body molecule for in vivo diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breas

43 dence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breas

44 of adjuvant therapy for stage I to III human epidermal growth factor receptor 2 (HER2)-positive breas

45 e: In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breas

46 In human epidermal growth factor receptor 2 (HER2)-positive breas

47 In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breas

48 r- and progesterone receptor-negative, human epidermal growth factor receptor 2 (HER2)-positive breas

49 ctively).Five-year BCSS was highest in human epidermal growth factor receptor 2 (HER2)-positive disea

50 ves clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive esoph

51 e signatures identifying patients with human epidermal growth factor receptor 2 (HER2)-positive invas

52 pproved for treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, meta

53 Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormo

54 y fused a recombinant sialidase to the human epidermal growth factor receptor 2 (HER2)-specific antib

55 imetry of (89)Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)-targeted imagi

56 as to determine whether imaging with a human epidermal growth factor receptor 2 (HER2)-targeted PET t

57 hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2).

58 edict the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2, encoded by the

59 short hairpin (sh)RNA cooperates with human epidermal growth factor receptor 2 (HER2/neu), leading t

60 e-specific membrane antigen (n = 7) or human epidermal growth factor receptor 2 (n = 5).

61 f breast cancer (luminal A, luminal B, human epidermal growth factor receptor 2 [currently known as E

62 ecular subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 enriched, and basal l

63 e receptor positive, and 19 (23%) were human epidermal growth factor receptor 2 positive.

64 which he was eligible on the basis of human epidermal growth factor receptor 2 positivity (>/= 1+ by

65 ogen/progesterone receptor status, and human epidermal growth factor receptor 2 positivity (all P < 0

66 l aptamer-based assay for detection of human epidermal growth factor receptor 2 protein (HER2) cancer

67 egimens based on estrogen receptor and human epidermal growth factor receptor 2 status was also asses

68 try) early breast cancer any nodal and human epidermal growth factor receptor 2 status, were randomly

69 basis of the number of lymph nodes and human epidermal growth factor receptor 2 status.

70 , 1.0 to 1.8) but not among those with human epidermal growth factor receptor 2 subtypes (HR, 1.2; 95

71 n receptor, progesterone receptor, and human epidermal growth factor receptor 2 was found to guide ch

72 c and epithelial cells, 205 kDa)-HER2 (human epidermal growth factor receptor 2) had significantly im

73 ceptor (PR) content, and HER2 content (human epidermal growth factor receptor 2).

74 eptor+, progesterone receptor+, and/or human epidermal growth factor receptor 2+ tumors.

75 eceptor, progesterone receptor, Ki-67, human epidermal growth factor receptor 2, and Elston grade) to

76 ogous cellular immunotherapy targeting human epidermal growth factor receptor 2, for which he was eli

77 well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, the androgen recepto

78 strogen and progesterone receptors and human epidermal growth factor receptor 2, the panel found suff

79 rogesterone receptors and negative for human epidermal growth factor receptor 2, with associated duct

80 vantages in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced bre

81 B (intermediate and high-risk, locally human epidermal growth factor receptor 2-negative BC).

82 proved IDFS in patients with high-risk human epidermal growth factor receptor 2-negative breast cance

83 tases, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cance

84 Results For 240 human epidermal growth factor receptor 2-negative patients you

85 For 145 human epidermal growth factor receptor 2-negative patients you

86 ry toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-

87 istinct molecular subgroups, except in human epidermal growth factor receptor 2-positive (HER2+) sloa

88 among breast cancer subtypes, with the human epidermal growth factor receptor 2-positive (HER2+) subt

89 umors (21% v 6%; P = .08), but not for human epidermal growth factor receptor 2-positive (luminal and

90 dard of care for adjuvant treatment of human epidermal growth factor receptor 2-positive breast cance

91 aluated in clinical trials for imaging human epidermal growth factor receptor 2-positive cancer patie

92 r adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage

93 Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human e

94 tGIV/cytoplasmic pYGIV was observed in human epidermal growth factor receptor 2-positive tumors (haza

95 esponse to RT, although, in our study, human epidermal growth factor receptor 2-positive tumors seeme

96 s-including hormone receptor-positive, human epidermal growth factor receptor 2-positive, and triple-

97 growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus

98 There was no amplification of the human epidermal growth factor receptor 2/ neu gene.

99 terone receptor are not expressed, and human epidermal growth factor-receptor 2 is not amplified or o

100 The transcriptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to

101 ed between estrogen receptor positive, human epidermal growth factor receptor-2 positive, and triple

102 ptors, including estrogen receptor and human epidermal growth factor receptor-2.

103 The human epidermal growth factor receptor 3 (HER3) is an interest

104 stant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expressio

105 terized by prominent expression of the human epidermal growth factor receptor 3 (HER3) on the cell su

106 al growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 3 (HER3), leading to pe

107 al growth factor receptor 2 (HER2) and human epidermal growth factor receptor 3 (HER3), was examined.

108 this study, we have shown that the RTK human epidermal growth factor receptor 4 (Her4, also known as

109 nges in the global and local organization of epidermal growth factor receptors across the cell surfac

110 Although oncogenic drivers such as epidermal growth factor receptor activation and Phosphat

111 ression of MAN2A1-FER in 4 cell lines led to epidermal growth factor receptor activation of BRAF, MEK

112 d EV release and mitogenic content including epidermal growth factor receptor and c-Src.

113 downregulated in ASD and that regulates the epidermal growth factor receptor and fibroblast growth f

114 ted metastasis suppressor interacts with the epidermal growth factor receptor and mediates its downst

115 he VLPs for peptides relevant to cancer from epidermal growth factor receptor and telomerase.

116 y on DUOX1-mediated activation of epithelial epidermal growth factor receptor and the protease calpai

117 echanism involving cysteine oxidation within epidermal growth factor receptor and the tyrosine kinase

118 ame extracellular vesicle instead displaying epidermal growth-factor receptor aptamer inhibited ortho

119 hat of wild-type FER, and phosphorylated the epidermal growth factor receptor at tyrosine 88 in its N

120 sistant to the drug erlotinib, which targets epidermal growth factor receptor (EGFR) (a host cofactor

121 he molecular testing of CRC tissues to guide epidermal growth factor receptor (EGFR) -targeted therap

122 d to evaluate Schwann cell proliferation and epidermal growth factor receptor (EGFR) activation in th

123 Inhibition of inflammation or epidermal growth factor receptor (EGFR) activity decreas

124 an adhesion-independent manner by dampening Epidermal Growth Factor Receptor (EGFR) activity.

125 ties of brain cancer cells expressing mutant epidermal growth factor receptor (EGFR) after drug inter

126 sary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanc

127 oteins gB and gH signal through the cellular epidermal growth factor receptor (EGFR) and alphavbeta3

128 ors, we document that HCMV activation of the epidermal growth factor receptor (EGFR) and downstream p

129 cation, through engagement and activation of epidermal growth factor receptor (EGFR) and integrins on

130 The epidermal growth factor receptor (EGFR) and its ligands

131 lled killing of cells which are positive for epidermal growth factor receptor (EGFR) and Ki-67.

132 on, Th2 cells required the expression of the epidermal growth factor receptor (EGFR) and of its ligan

133 upstream effector, the role of NDRG1 on the epidermal growth factor receptor (EGFR) and other member

134 It selectively interacts with epidermal growth factor receptor (EGFR) and serves as a

135 epithelial cell adhesion molecule (EpCAM) or epidermal growth factor receptor (EGFR) and the cartridg

136 seek to characterize the interaction between epidermal growth factor receptor (EGFR) and the cytoplas

137 motes translation of certain mRNAs including epidermal growth factor receptor (EGFR) and the Hippo pa

138 In the model, epidermal growth factor receptor (EGFR) and vascular end

139 has also been proven to positively regulate epidermal growth factor receptor (EGFR) and WNT signalin

140 Receptor tyrosine kinases MET and epidermal growth factor receptor (EGFR) are critically i

141 Mutations in K-Ras and epidermal growth factor receptor (EGFR) are mutually exc

142 BACKGROUND & AIMS: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-li

143 Aberrant amplification and mutations of epidermal growth factor receptor (EGFR) are the most com

144 or receptor bound 2 (GRB2) to phosphorylated epidermal growth factor receptor (EGFR) as a model syste

145 Although epidermal growth factor receptor (EGFR) can directly act

146 cally interact, we searched for modifiers of epidermal growth factor receptor (EGFR) dependency by pe

147 Epidermal growth factor receptor (EGFR) family members p

148 ressed in keratinocytes, where together with epidermal growth factor receptor (EGFR) forms a signalin

149 0 and CIN85, which results in the removal of epidermal growth factor receptor (EGFR) from the surface

150 ce of this interaction is the removal of the epidermal growth factor receptor (EGFR) from the surface

151 o detect mutations of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene.

152 Epidermal growth factor receptor (EGFR) has been implica

153 tors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found succe

154 Current knowledge suggests a role for epidermal growth factor receptor (EGFR) in cholangiocyte

155 Despite a well-established role for the epidermal growth factor receptor (EGFR) in tumorigenesis

156 The role of epidermal growth factor receptor (EGFR) inhibition in ch

157 ) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rocile

158 iRNA signature predictive of response to the epidermal growth factor receptor (EGFR) inhibitor, erlot

159 d ALK-translocated lung cancers treated with epidermal growth factor receptor (EGFR) inhibitors and A

160 Reversible epidermal growth factor receptor (EGFR) inhibitors promp

161 neration therapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remai

162 Epidermal growth factor receptor (EGFR) interacts with i

163 of ubiquitin interaction for the sorting of epidermal growth factor receptor (EGFR) into ILVs for ly

164 The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthroug

165 The epidermal growth factor receptor (EGFR) is a clinically

166 The epidermal growth factor receptor (EGFR) is a prototypica

167 The epidermal growth factor receptor (EGFR) is a receptor ty

168 Epidermal growth factor receptor (EGFR) is central to ep

169 ecific DNA demethylation and upregulation of epidermal growth factor receptor (EGFR) ligands amphireg

170 E2 upregulated epidermal growth factor receptor (EGFR) ligands Egf, Ere

171 roteases are the enzymes that release active epidermal growth factor receptor (EGFR) ligands in Droso

172 paring the concurrent administration of anti-epidermal growth factor receptor (EGFR) monoclonal antib

173 l cancer (mCRC) to detect resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antib

174 paring the concurrent administration of anti-epidermal growth factor receptor (EGFR) monoclonal antib

175 ll-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typica

176 small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations.

177 Here, using a beta-cell specific epidermal growth factor receptor (EGFR) null mouse, we s

178 8% (96/348) of patients were found to harbor epidermal growth factor receptor (EGFR) or Kristen rat s

179 Different data support a role for the epidermal growth factor receptor (EGFR) pathway during l

180 accompanied by an increase in the levels of epidermal growth factor receptor (EGFR) phosphorylation,

181 epithelial cells had elevated ligand-induced epidermal growth factor receptor (EGFR) phosphorylation.

182 The epidermal growth factor receptor (EGFR) plays a critical

183 The epidermal growth factor receptor (EGFR) plays a critical

184 ogeneous expression of amplified and mutated epidermal growth factor receptor (EGFR) presents a subst

185 Epidermal growth factor receptor (EGFR) regulates many c

186 ly, loss of NRF2 led to defects in autocrine epidermal growth factor receptor (EGFR) signaling and ox

187 ular endothelial growth factor (VEGFR)-2 and epidermal growth factor receptor (EGFR) signaling by enh

188 Epidermal growth factor receptor (EGFR) signaling has a

189 maternal diet were mediated by a decrease in epidermal growth factor receptor (EGFR) signaling in NPC

190 Epidermal growth factor receptor (EGFR) signaling is a k

191 Epidermal Growth Factor Receptor (EGFR) signaling is ess

192 In addition, epidermal growth factor receptor (EGFR) signaling is reg

193 Aberrant epidermal growth factor receptor (EGFR) signaling is wid

194 Focusing on the epidermal growth factor receptor (EGFR) signaling networ

195 e stem cells (FSCs) of the Drosophila ovary, Epidermal Growth Factor Receptor (EGFR) signaling promot

196 Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field

197 Epidermal growth factor receptor (EGFR) signalling is ac

198 signalosome to prevent ectopic expression of Epidermal growth factor receptor (EGFR) target genes.

199 rized a bi-functional molecule comprising of epidermal growth factor receptor (EGFR) targeted nanobod

200 l-validated solid tumor targets, such as the epidermal growth factor receptor (EGFR) that effectively

201 Current anti-epidermal growth factor receptor (EGFR) therapy for oral

202 tamer previously selected for binding to the epidermal growth factor receptor (EGFR) to create a bifu

203 Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumour

204 Signaling from epidermal growth factor receptor (EGFR) to extracellular

205 Mig6 directly interacts with epidermal growth factor receptor (EGFR) to suppress the

206 Epidermal growth factor receptor (EGFR) tyrosine kinase

207 Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase

208 ER-MVB contacts additionally function in epidermal growth factor receptor (EGFR) tyrosine kinase

209 improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase

210 EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase

211 Here, we show that lnc-epidermal growth factor receptor (EGFR) upregulation in

212 Interferon gamma (IFNgamma) and the epidermal growth factor receptor (EGFR) utilize Janus ki

213 Stimulation of the epidermal growth factor receptor (EGFR) with EGF, the be

214 of CETN3 and SKP1 to elevated expression of epidermal growth factor receptor (EGFR), and SKP1 loss a

215 regulate chloride secretion, centred on the epidermal growth factor receptor (EGFr), are discussed.

216 several receptor tyrosine kinases, including epidermal growth factor receptor (EGFR), insulin growth

217 the wound repair pathway, controlled by the epidermal growth factor receptor (EGFR), is critical to

218 EMMs of lung adenocarcinoma driven by mutant epidermal growth factor receptor (EGFR), mutant Kirsten

219 o may benefit from therapies that target the epidermal growth factor receptor (EGFR), such as cetuxim

220 ve been reported to regulate the function of epidermal growth factor receptor (EGFR), the effect of p

221 gnaling between alpha5beta1 integrin and the epidermal growth factor receptor (EGFR), which is influe

222 verexpression lead to aberrant activation of epidermal growth factor receptor (EGFR), which subsequen

223 CCN1 effectively inhibits epidermal growth factor receptor (EGFR)-dependent hepato

224 The epidermal growth factor receptor (EGFR)-directed tyrosin

225 ell lines, which was accompanied by enhanced epidermal growth factor receptor (EGFR)-mediated mitogen

226 lthough mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small

227 ing brain and leptomeningeal metastases-from epidermal growth factor receptor (EGFR)-mutant non-small

228 rsor cells, a well-characterized paradigm of epidermal growth factor receptor (EGFR)-Ras-ERK signalin

229 lar endothelial growth factor A (VEGF-A) and epidermal growth factor receptor (EGFR)-targeted fluores

230 (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase

231 onformation of the external (ecto) domain of Epidermal Growth Factor Receptor (EGFR).

232 e demonstrated that RCN2 interacted with the epidermal growth factor receptor (EGFR).

233 pecific interaction of an engineered gD with epidermal growth factor receptor (EGFR).

234 eceptor-alpha and reciprocal upregulation of epidermal growth factor receptor (EGFR).

235 ment is driven by detachment-induced loss of epidermal growth factor receptor (EGFR).

236 ped them into siRNA carriers targeted to the epidermal growth factor receptor (EGFR).

237 f the gene encoding receptor tyrosine kinase epidermal growth factor receptor (EGFR).

238 g by ADAMs [e.g., ligands and receptors from epidermal growth factor receptor (EGFR)/ErbB and tumor n

239 The epidermal growth factor receptor (EGFR)/ErbB family of r

240 ntibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-r

241 d to letrozole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine ki

242 es ErbB signaling by inhibiting formation of epidermal growth factor receptor (EGFR)/human epidermal

243 protein kinase CK2 and the wild-type/mutated epidermal growth factor receptor (EGFR/EGFRvIII), which

244 ter (177)Lu and to panitumumab for targeting epidermal growth factor receptors (EGFR) ((177)Lu-T-AuNP

245 LCN(-/-) cells display slower trafficking of epidermal growth factor receptors (EGFR) from early to l

246 tective antigen, PA) which was redirected to Epidermal Growth Factor Receptors (EGFR) or to human EGF

247 alterations, are barriers to effective anti-epidermal-growth-factor-receptor (EGFR) therapy.

248 urface receptor on these cells and vesicles (epidermal growth factor receptor, EGFR) reduces the inte

249 The human epidermal growth factor receptor, EGFR/ERBB/HER, family

250 Cell surface levels of epidermal growth factor receptors (EGFRs) are thought to

251 on of glioblastoma cells expressing a mutant epidermal growth factor receptor (EGFRvIII) is responsib

252 nests that can mediate signals via the human epidermal growth factor receptor (ErbB) tyrosine kinase

253 having a proven role in activating the human epidermal growth factor receptor/ERBB pathway.

254 ced non-small-cell lung cancer (NSCLC) whose epidermal growth factor receptor expression status is po

255 Members of the epidermal growth factor receptor family (ErbB family) po

256 rst-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive m

257 n G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocki

258 Human epidermal growth factor receptor (HER) 3 is aberrantly o

259 ons between the catalytically impaired human epidermal growth factor receptor (HER3/ERBB3) and its ca

260 Further, epidermal growth factor receptor I (EGFR)-binding peptid

261 Selective activation of epidermal growth factor receptor in renal proximal tubul

262 Erlotinib is an epidermal growth factor receptor inhibitor approved for

263 Purpuric drug eruptions caused by epidermal growth factor receptor inhibitors are uncommon

264 enter with purpuric skin lesions after using epidermal growth factor receptor inhibitors from January

265 systemic antibiotic treatment; the doses of epidermal growth factor receptor inhibitors were also ch

266 aracterize purpuric skin eruptions caused by epidermal growth factor receptor inhibitors.

267 y rarely been reported in patients receiving epidermal growth factor receptor inhibitors.

268 ulation of SOCS1 decreased the expression of epidermal growth factor receptor, Ins-Ralpha, and fibrob

269 the FER kinase inhibitor crizotinib and the epidermal growth factor receptor kinase inhibitor canert

270 ifferentiation by forming a complex with the epidermal growth factor receptor, leading to activation

271 Parabens and human epidermal growth factor receptor ligand cross-talk in br

272 us cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical sig

273 Following gut epithelial damage, epidermal growth factor receptor/mitogen-activated prote

274 patients, 8 with and 9 without an activating epidermal growth factor receptor mutation (exon 19 delet

275 arcinoma (NSCLC) patients with an activating epidermal growth factor receptor mutation who were treat

276 pecies partition analysis, we identified the epidermal growth factor receptor on endophilin B1 vesicl

277 e to overexpression of receptors such as the epidermal growth factor receptor, or mutation of signall

278 alyses of MPNSTs arising in neuregulin-1 and epidermal growth factor receptor-overexpressing mice and

279 Eps15 (epidermal growth factor receptor pathway substrate 15)-h

280 4) and endocytosis adaptor proteins Numb and epidermal growth factor receptor pathway substrate 15.

281 Genes involved in the tumor protein 53 and epidermal growth factor receptor pathways have been exte

282 Inhibition of the epidermal growth factor receptor represents one of the m

283 ed epitopes on mouse serum albumin and human epidermal growth factor receptor, respectively.

284 They regulate epidermal growth factor receptor signalling in Drosophil

285 bilizing protein cortactin downstream of the epidermal growth factor receptor-Src-Arg kinase cascade

286 ol myristate acetate, Gq/11-coupled GPCR, or epidermal growth factor receptor stimulation promotes be

287 inic to select patients who may benefit from epidermal growth factor receptor-targeted therapy in non

288 (PI3K) mediate the increase independently of epidermal growth factor receptor transactivation.

289 rone receptor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,41

290 age, race, and hormone receptor (HR)/ human epidermal growth factor receptor type 2 (HER2) status.

291 Previous studies demonstrated that the human epidermal growth factor receptor type 2 (HER2)-targeting

292 d considerable inhibitory percentage against Epidermal Growth Factor Receptor tyrosine kinase (EGFR-T

293 Epidermal growth factor receptor tyrosine kinase inhibit

294 tation, disease progression after first-line epidermal growth factor receptor tyrosine kinase inhibit

295 The epidermal growth factor receptor tyrosine kinase inhibit

296 itumab and whether the drug can overcome the epidermal growth factor receptor tyrosine kinase inhibit

297 cell mitogen neuregulin-1 or overexpress the epidermal growth factor receptor validate observations i

298 of EVT differentiation, the transition from epidermal growth factor receptor(+) villous cytotrophobl

299 binding fragments F(ab')2 and Fab) targeting epidermal growth factor receptor were labeled with Alexa

300 and c78(f/+) pancreata leads to reduction of epidermal growth factor receptor, which is critical for